April 2010
BioWorld Today;4/12/2010, Vol. 21 Issue 69, p5
This section offers news briefs in the biotechnology industry, including the completion of a public offering by Ardea Biosciences Inc. and a common stock purchase agreement formed by Generex Biotechnology Corp. with Seaside 88 LP.


Related Articles

  • Financings Roundup.  // BioWorld Today;4/11/2011, Vol. 22 Issue 69, p4 

    The article reports that Misgav, Israel-based Medgenics Inc. has priced its initial public offering in the U.S. of 2.46 million shares of common stock at 4.54 U.S. dollars per share and redeemable common stock purchase warrants at 46 cents per warrant.

  • Week in Review.  // BioWorld Insight;9/24/2012, Vol. 20 Issue 39, p5 

    This section offers news briefs in the biotechnology industry. A 32 million dollar public offering was completed by Pluristem Therapeutics Inc. A stock purchase agreement was signed between Advanced Cell Technology Inc. and Lincoln Park Capital Fund LLC. Compliance was regained by Cell...

  • FINANCINGS ROUNDUP.  // BioWorld Today;9/25/2009, Vol. 20 Issue 185, p7 

    This section offers news briefs on biotechnology in the U.S. DOR BioPharma Inc. has entered common stock purchase agreements with institutional investors estimated to be worth 3.85 million U.S. dollars. In other news, Vivus Inc. has closed its public offering allowing underwriters to exercise in...

  • Insulet to sell 6 million shares at $10.25 each.  // Medical Device Daily;11/2/2009, Vol. 13 Issue 211, p2 

    The article announces that Insulet has priced its public offering of 6 million shares of common stocks at 10.25 U.S. dollars a share. Furthermore, the underwriters for the public offering have been granted an over-allotment option to purchase up to an additional 900,000 shares. The net proceeds...

  • DexCom closes on $48 million; SpectraScience raises $6M.  // Medical Device Daily;2/6/2009, Vol. 13 Issue 24, p3 

    The article reports that DexCom has closed its previously disclosed public offering of its common stock at a price of $3 per share. A total of 150,000 additional shares has been purchased by Terrance Greeg, the company's president and chief executive officer (CEO), at $3.12 per share. The gross...

  • Financings Roundup.  // BioWorld Today;8/6/2009, Vol. 20 Issue 150, p3 

    The article reports on a public offering of 22.2 million shares priced at 4.50 U.S. dollars a piece launched by Inspire Pharmaceuticals Inc. The company is expected to raise about 100 million U.S. dollars through the public offering. The company also has plans to grant underwriter Deutsche Bank...

  • UCB to divest selected assets to GSK for E515 million.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p20 

    The article reports on the agreement of UCB, a Belgium-based biopharmaceutical and specialty chemical company, with GlaxoSmithKline (GSK) to sell UCB business and its affiliates to the chosen emerging markets for a cash compensation of €515 million. The commercial operations and product...

  • AIG Closes on Sale of ALICO to MetLife. Hersch, Warren S. // National Underwriter / Life & Health Financial Services;11/8/2010, Vol. 114 Issue 21, p28 

    The article reports on the stock purchase agreement of American International Group Inc. (AIG) with Metropolitan Life Insurance Co. It states that AIG has sold American Life Insurance Co. (ALICO) for about 16 billion dollars, including 7.2 billion dollars in cash and about 8.8 billion dollars in...

  • Process counts in determining a firm's style. McDonald, John // Pensions & Investments;9/1/1997, Vol. 25 Issue 18, p27 

    Looks at the approach used by pensions and investment firms in assessing how to purchase stock and how that approach determines the style of the firm. How style should not have anything to do with the size of the stock purchase; What makes the terminology of style confusing; How defining styles...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics